Peningkatan antikoagulan drive baru populer dalam pengobatan fibrilasi atrial--T-REC-komunitas reptil-semarang--KSE-komunitas satwa eksotik

SILAHKAN MENGGUNAKAN " MESIN TRANSLATE "..GOOGLE TRANSLATE
DISAMPING KANAN INI.............

PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS

.................


T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA


More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
..................................
KSE – KOMUNITAS SATWA EKSOTIK – EXOTIC PETS COMMUNITY-- INDONESIA
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
 KSE = KOMUNITAS SATWA EKSOTIK

MENGATASI KENDALA MINAT DAN JARAK

KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com

GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI   :  089617123865-08995557626

.........................

Peningkatan antikoagulan drive baru populer dalam pengobatan fibrilasi atrial

Date:

July 22, 2015

Source:

University of Michigan Health System

Summary:

Pengencer darah baru populer mungkin berada di balik lonjakan kunjungan dokter  untuk mengobati detak jantung yang tidak teratur , menurut sebuah studi baru . Obat-obatan banyak diiklankan membuat mengelola fibrilasi atrial sederhana daripada terapi yang lebih tua seperti Warfarin . Di antara pemain baru , antikoagulan oral yang langsung paling diresepkan adalah Xarelto .

........... Di Amerika Serikat dokter memetakan lebih dari 2,83 juta kunjungan pengobatan pada kuartal terakhir 2014 , naik dari 2,05 juta pada awal tahun 2009 , untuk penggunaan antikoagulan .

Tren peningkatan kunjungan sebagian besar didorong oleh popularitas antikoagulan oral baru langsung ( DOAC ) , pengencer darah yang telah banyak diiklankan sebagai mudah digunakan . Penggunaannya tiga kali lipat 2013-2014 .

Dokter beralih ke antikoagulan untuk menjaga aliran darah yang sehat di antara pasien dengan atrial fibrilasi irama jantung yang abnormal atau bekuan darah di kaki dan paru-paru yang disebut tromboemboli vena .....more

Popular new
anticoagulants drive increase in atrial fibrillation treatment

Date:

July 22, 2015

Source:

University of Michigan Health System

Summary:

Popular new blood thinners may be behind a surge in doctor visits to treat
an irregular heartbeat, according to a new study. The heavily advertised
medicines make managing atrial fibrillation simpler than older therapies like
Warfarin. Among the new players, the most prescribed direct oral anticoagulant
is Xarelto.

.......................

Across the United States doctors charted more than 2.83 million treatment
visits in the last quarter of 2014, up from 2.05 million at the start of 2009,
for use of anticoagulants.

The upward trend in visits is largely driven by the popularity of new
direct oral anticoagulants (DOAC), blood thinners that have been heavily
advertised as simple to use. Their use tripled from 2013-2014.

Doctors turn to anticoagulants to keep a healthy blood flow among patients
with the abnormal heart rhythm atrial fibrillation or blood clots in the legs
and lungs called venous thromboembolism.

The findings were published online ahead of print in The American
Journal of Medicine and suggest more people may be getting the
treatment they need for atrial fibrillation.

"The data provides a promising outlook about atrial fibrillation which
is known for being undertreated," says lead author Geoffrey Barnes, M.D.,
MSc., cardiologist at the University of Michigan Health System and researcher
at the Institute for Healthcare Policy and Innovation. "When we don't
treat atrial fibrillation, patients are at risk for stroke. By seeking
treatment, patients set themselves up for better outcomes."

Warfarin therapy dominated stroke prevention in atrial fibrillation until
the first in the new class of anticoagulants was approved in 2010.

The newly designed medicines have fewer food and drug interactions and do
not require frequent blood checks the way warfarin does.

Despite their costs, the arrival of the DOACs made the prospect of stroke
prevention less burdensome.

For the study, researchers analyzed the IMS Health National Disease and
Therapeutic Index which surveys approximately 4,800 physicians identified
through a random audit of the American Medical Association and the American
Osteopathic Association. The survey captures information on all clinic visits
representing about 350,000 office visits each quarter.

The findings show warfarin therapy visits declined between 2009 and 2014,
while direct oral anticoagulant treatment visits have risen over one million per
quarter since their introduction in 2010.

DOACs have been quickly adopted and risen to nearly match the use of
warfarin. Last year, 57 percent of anticoagulant visits were related to
warfarin use compared to 43 percent related to DOACs, according to the study.

Dabigatran accounted for the majority of prescriptions for DOACs from
2010-2012, but as other drugs have come on the market, rivaroxaban (Xarelto® )
has become the most commonly prescribed oral anticoagulant during atrial
fibrillation office visits, the study showed.







Story Source:

The above post is reprinted from materials provided byUniversity
of Michigan Health System. Note: Materials may be edited
for content and length.







Journal Reference:

1.   
Geoffrey D. Barnes, Eleanor Lucas, G. Caleb Alexander, Zachary D.
Goldberger. National Trends in Ambulatory Oral Anticoagulant Use. The
American Journal of Medicine, 2015; DOI: 10.1016/j.amjmed.2015.05.044

http://www.sciencedaily.com/releases/2015/07/150722082039.htm

Share this: